Cougar soars on buyout; Aastrom sinks
May 22, 2009 at 10:35 AM EDT
BOSTON (MarketWatch) - News that Johnson & Johnson plans to buy Cougar Biotechnology for about $1 billion sent Cougar shares soaring early Friday, while shares of Aastrom Biosciences tumbled on safety concerns about their experimental stem-cell therapy for heart failure.
